Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-08-23Clinical Trial Update: Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating inetetamab in combination with pyrotinib for HER2-mutant or amplified advanced non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2021-08-20Clinical Trial Update: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) [Phase 3]
A Phase 3 clinical trial comparing TQB2450 plus Anlotinib to a comparator in first-line non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-08-20Clinical Trial Update: ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants [Phase 3]
Phase 3 trial comparing brigatinib to crizotinib in ALK-positive advanced non-small cell lung cancer completed with posted results.
-
FDA approval · 2021-08-19FDA Approved: ZYKADIA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for ZYKADIA (ceritinib) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC [Phase 1, Phase 2]
Phase Ib/II trial evaluating fecal microbiota transplant in combination with nivolumab for metastatic or inoperable melanoma and NSCLC; stat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS [Phase 2]
Phase 2 clinical trial investigating AZD9291 (osimertinib) in non-small cell lung cancer patients with EGFR T790M mutation and brain or lept…
-
CLINICAL_TRIALS trial_result · 2021-08-13Clinical Trial Update: A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. [Phase 2]
Phase II trial evaluating camrelizumab plus famitinib as adjuvant therapy for stage II-IIIA non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC [Phase 2]
Phase 2 trial evaluating sintilimab, anlotinib hydrochloride, and platinum-containing chemotherapy in metastatic/recurrent non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: FRAME-001 Personalized Vaccine in NSCLC [Phase 2]
Phase 2 clinical trial update for FRAME-001, a personalized vaccine in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites [NA]
Clinical trial update for Canady Helios cold plasma scalpel at surgical margins and macroscopic tumor sites; status and results data are unc…
-
CLINICAL_TRIALS trial_result · 2021-08-06Clinical Trial Update: A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC [Phase 2]
Phase 2 trial evaluating safety of concurrent durvalumab with concomitant radiotherapy and consolidation durvalumab in Chinese patients with…
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality [Phase 3]
Phase 3 trial evaluating adjuvant melatonin for prevention of lung cancer recurrence and mortality has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating durvalumab with or without SBRT in clinical stage I–IIIA non-small cell lung cancer has completed and posted result…
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA [Phase 2]
Phase 2 trial evaluating osimertinib as first- or second-line treatment for EGFR-mutated non-small cell lung cancer using circulating tumor …
-
EMA withdrawal · 2021-07-29EMA Withdrawn: Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited) (pemetrexed ditromethamine) — Pfizer Europe MA EEIG
The EMA status indicates the pemetrexed product previously marketed by Hospira/Pfizer has been withdrawn. It was indicated for non-small cel…
-
CLINICAL_TRIALS trial_result · 2021-07-29Clinical Trial Update: An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC [Phase 2]
Phase 2 open-label study of nivolumab monotherapy in advanced or metastatic squamous cell non-small cell lung cancer previously treated; stu…
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. [Phase 3]
Phase 3 trial comparing osimertinib to placebo in patients with stage IB-IIIA non-small cell lung cancer after complete resection (with or w…
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of anlotinib and almonertinib as first-line therapy for brain metastases in EGFR mutation-…
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread [Phase 1, Phase 2]
A phase 1/2 study evaluating safety and activity of nivolumab with daratumumab in patients with pancreatic cancer, non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2021-07-23Clinical Trial Update: Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors [Phase 2]
Phase 2 trial investigating SHR-1701 plus BP102 in advanced or metastatic non-squamous non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial exploring nivolumab with ipilimumab, with or without chemotherapy, as first-line treatment for stage IV non-small cell lung ca…
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression [Phase 2]
Phase 2 clinical trial evaluating furmonertinib in combination with radiotherapy for non-small cell lung cancer with oligoprogression.
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety and anti-tumor activity of NK cell therapy SNK01 in combination with chemotherapy or chemotherapy plus cet…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy [Phase 2, Phase 3]
A Phase II/III clinical trial evaluating neoadjuvant therapy with Pablizumab combined with Apatinib and chemotherapy in resectable non-small…
-
CLINICAL_TRIALS trial_result · 2021-07-20Clinical Trial Update: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation [Phase 3]
Phase 3 trial evaluating icotinib as adjuvant therapy versus standard chemotherapy in stage II-IIIA non-small cell lung cancer with EGFR mut…